News

The occurrence of blood clots in the veins of scleroderma patients is rare and does not change patients’ survival rates, a new Canadian study shows. Still, researchers see a need for improved understanding of venous thromboembolism (VTE) in these patients. The study, “Venous Thromboembolism in Systemic Sclerosis: Prevalence,…

A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…

Therapeutic plasma exchange, which aims to treat systemic sclerosis (SSc) by clearing the blood of antibodies, cytokines and other factors that might promote disease progression, shows potential as a therapy, a review study reported. But a well-designed clinical trial, incorporating equipment and techniques that have come into use since therapeutic…

Increased levels of two proteins produced during acute inflammation can help predict pulmonary involvement in patients with diffuse systemic sclerosis, a study shows. Patients with diffuse systemic sclerosis who also have developed lung disease were found to have significantly higher levels of C-reactive protein (CRP) and serum amyloid A…

Almost a quarter of systemic sclerosis (SSc) patients with reduced gas exchange develop pulmonary hypertension (PH) within three years, according to a recent study that used right heart catheterization to measure pulmonary arterial pressures. Regular tests to assess PH, including right heart catheterization (RHC), might be useful in…

Nailfold capillary damage was found to be a predictor of mortality in scleroderma patients, according to researchers from Australia. The study, “The role of Nailfold Capillary Dropout on Mortality in Systemic Sclerosis,” was published in the Internal Medicine Journal. Microvasculopathy, which refers to the degeneration…

Major healthcare organizations are throwing their support behind an initiative called “Let MI Doctors Decide” intended to improve patient access to prescribed medicines for scleroderma and other autoimmune disorders in Michigan. “Let MI Doctors Decide” is spearheaded by the American Autoimmune Related Diseases Association (AARDA). Organizations joining a new…